How Gilead Profited by Slow-Walking a Promising H.I.V. Therapy


Gilead delayed a new version of a drug, allowing it to extend the patent life of a blockbuster line of medications, internal documents show.

Previous Story

China’s Government Offers Love, but Entrepreneurs Aren’t Buying It

Next Story

Altice USA Said to Be Considering a Sale of Cheddar News